The Yale School of Medicine Section of Cardiovascular Medicine and the Section of Rheumatology, Allergy, and Immunology offer a Cardio-Rheumatology Program to provide personalized cardiovascular risk assessment and treatment for patients with autoimmune diseases, including rheumatoid arthritis, systemic lupus, scleroderma, psoriatic arthritis, and vasculitis.
Co-directed by Margaret L. Furman, MD, MPH, assistant professor at the Yale School of Medicine, the program specializes in risk and medication management.
The economic impact on the State of Connecticut from its fifteen non-profit independent colleges and universities is $16.5 billion annually, according to a just completed study released by the Connecticut Conference of Independent Colleges (CCIC).
“Connecticut’s independent colleges and universities are known for preparing students for career success and engaged citizenship, advancing research and knowledge, and promoting arts and culture, but they also have a tremendous impact on their local and regional economies,” said Rhona Free, Ph.D., President of the University of Saint Joseph and Chair of the CCIC Board of Directors.
The newhavenbiz annual Power 25 list features individuals based in the Greater New Haven region who hold significant influence within their organizations and the broader business community.
This year’s group, featuring leaders of universities, global nonprofit organizations, real estate agencies, banks, manufacturers, law firms, and economic development groups, includes includes leaders from Siduma Therapeutics, Shipman & Goodwin, Marcum, and Yale Ventures.
|
||||||||||||||||||||||||||
|
||||||||||||||||||||||||||
|
CYduct Diagnostics recently won a prestigious grant award for their work within breast cancer risk assessment.
The grant, generously awarded by the Sharon D. Lund Foundation, will allow CYduct’s clinicians, in collaboration with leading breast cancer advocacy groups, to continue their work in developing what the company believes will be a revolutionary proteomic breast cancer risk assessment test. This test will utilize targeted biomarkers associated with the progression of breast cancer.
Guilford-based Hyperfine reports it has secured FDA approval of a software update for its portable MRI device that will boost its image quality and accuracy.
With the new software, the company’s Swoop portable MRI system shows improved performance in diffusion-weighted imaging (DWI), which results in better quality MRI images, Hyperfine says.
New Haven’s Biohaven has earned FDA “Fast Track” designation for its drug to treat muscle loss in spinal muscular atrophy patients.
Biohaven’s drug, taldefgrobep alfa, is scheduled for a Phase 3 clinical trial and had previously earned orphan drug designation for its use in spinal muscular atrophy, a rare and progressively debilitating motor-neuron disease.
Lumendi reports that it has received FDA 510(k) clearance for DiLumen EZ¹, a single-use, disposable endotherapy device for endoscopic mucosal resections (EMR) and difficult colonoscopies. The new, more cost-effective design, based on the long-standing success of the DiLumen EZ-Glide platform, has been modified and streamlined.
“The DiLumen EZ¹ device will meaningfully enhance our product portfolio by meeting more procedure specific needs for complex polyp resections which are conducted through EMR. Globally, EMR procedures represent the majority share of the over one million polyp resections conducted, annually,” said Dr. Peter Johann, Chief Executive Officer of Lumendi, Ltd.
Cybrexa Therapeutics has reported the appointments of Laurie Kenvin as Vice President of Clinical Operations and Nick Saccomano, Ph.D., to the Company’s Scientific Advisory Board (SAB).
“We are excited to be strengthening our organization with the addition of Laurie and Nick,” said Per Hellsund, President and CEO, Cybrexa. “They bring over 50 years combined therapeutic and clinical expertise; both critical to the expansion of our leadership and advisory teams as we expand our CBX-12 clinical development program into Phase 2 clinical trials and further advance our other important pipeline assets.”
Cybrexa Therapeutics has reported the appointments of Laurie Kenvin as Vice President of Clinical Operations and Nick Saccomano, Ph.D., to the Company’s Scientific Advisory Board (SAB).
“We are excited to be strengthening our organization with the addition of Laurie and Nick,” said Per Hellsund, President and CEO, Cybrexa. “They bring over 50 years combined therapeutic and clinical expertise; both critical to the expansion of our leadership and advisory teams as we expand our CBX-12 clinical development program into Phase 2 clinical trials and further advance our other important pipeline assets.”